Progress in Radiopharmacy: Developments in Nuclear Medicine, cartea 22
Editat de August P. Schubiger, Gerrit Westeraen Limba Engleză Hardback – 31 dec 1991
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (1) | 1352.40 lei 6-8 săpt. | |
| SPRINGER NETHERLANDS – 25 sep 2012 | 1352.40 lei 6-8 săpt. | |
| Hardback (1) | 1359.25 lei 6-8 săpt. | |
| SPRINGER NETHERLANDS – 31 dec 1991 | 1359.25 lei 6-8 săpt. |
Din seria Developments in Nuclear Medicine
- 5%
Preț: 361.44 lei - 5%
Preț: 374.56 lei - 5%
Preț: 3076.55 lei - 5%
Preț: 1057.37 lei - 5%
Preț: 362.13 lei - 5%
Preț: 2029.48 lei - 5%
Preț: 359.48 lei - 5%
Preț: 1357.81 lei - 5%
Preț: 1358.36 lei - 5%
Preț: 627.98 lei - 5%
Preț: 355.62 lei - 5%
Preț: 690.22 lei - 5%
Preț: 683.18 lei - 5%
Preț: 353.69 lei - 5%
Preț: 683.87 lei - 5%
Preț: 2047.74 lei - 5%
Preț: 687.74 lei - 5%
Preț: 1054.76 lei - 5%
Preț: 687.93 lei - 5%
Preț: 1062.48 lei - 5%
Preț: 354.38 lei - 5%
Preț: 680.90 lei - 5%
Preț: 1052.31 lei - 5%
Preț: 349.65 lei - 5%
Preț: 1055.49 lei - 5%
Preț: 1055.64 lei - 5%
Preț: 1057.37 lei - 5%
Preț: 1053.55 lei - 5%
Preț: 694.44 lei - 5%
Preț: 348.23 lei - 5%
Preț: 362.13 lei - 15%
Preț: 565.36 lei - 5%
Preț: 365.66 lei - 5%
Preț: 361.08 lei - 5%
Preț: 355.07 lei
Preț: 1359.25 lei
Preț vechi: 1430.79 lei
-5% Nou
Puncte Express: 2039
Preț estimativ în valută:
240.53€ • 280.50$ • 211.19£
240.53€ • 280.50$ • 211.19£
Carte tipărită la comandă
Livrare economică 15-29 ianuarie 26
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780792315254
ISBN-10: 0792315251
Pagini: 228
Ilustrații: XIII, 228 p.
Dimensiuni: 155 x 235 x 16 mm
Greutate: 0.53 kg
Ediția:1992
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Nuclear Medicine
Locul publicării:Dordrecht, Netherlands
ISBN-10: 0792315251
Pagini: 228
Ilustrații: XIII, 228 p.
Dimensiuni: 155 x 235 x 16 mm
Greutate: 0.53 kg
Ediția:1992
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Nuclear Medicine
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
1. Future development of radiopharmaceuticals.- One: Brain receptor ligands.- 2. Necessary conditions for a multicenter study with a new radiopharmaceutical. Example: 123 I-Iomazenil.- 3. Design and evaluation of new receptor ligands exemplified by recent developments in the pharmacology of the benzodiazepine receptor.- 4. Studies on substituted benzamides as brain dopamine receptor imaging agent.- Two: Technetium-99m and other radionuclide generators.- 5. Cell labeling in radiopharmacy: what can radiolabeled monoclonal antibodies offer?.- 6. Automated systems for the preparation of Tc-kits in hospitals.- 7. New radiopharmaceuticals based on Technetium.- 8. The development of new radionuclide generator systems for nuclear medicine applications.- Three: Positron Emission Tomography.- 9. Production and application of oxygen-15; radiopharmacy aspects.- 10. Clinical aspects of positron emission tomography.- 11. Carbon-11 radiopharmaceuticass - radiopharmacy aspects.- 12. Production and distribution of 18F-radiopharmaceuticals - 2-deoxy-2[18F]fluoro-D-Glucose — radiopharmaceutic aspects.- 13. Preclinical data necessary to assess PET examinations.- Four: Rules and regulations.- 14. EEC directives and radiopharmaceuticals: the point of view of the radiopharmaceutical industry.- 15. European regulations and guidelines for the registration of radiopharmaceuticals.- 16. General guidelines for the quality assurance and quality control of short-lived radiopharmaceuticals.- 17. Legal and regulatory aspects of PET radiopharmaceuticals in the USA.- Five: Education.- 18. The development of a co-ordinated training programme in radiopharmacy in Europe.- 19. Experiences in postgraduate education of radiochemists and radiopharmacists at Berlin- Buch.- Six: Appendix.- 20. Monoclonalchimeric antibodies to HIV-1 - Clinical perspectives.- 21. Tracer technique - the Swiss story.
Recenzii
'...results in a publication that should serve as a useful resource for radioharmacists, radiopharmaceutical scientists, and nuclear medicine clinicians working in academic and research environments.' Clinical Nuclear Medicine Sep. 1992